Novartis Challenger To Alexion Advances In Rare Kidney Disease

Ultomiris Head-to-Head Planned

 
• By Andrew McConaghie
Novartis NIBR Cambridge, MA
Analysts at Jefferies think iptacopan could hit $3.6bn in peak annual sales. • Source: Alamy

More from Business

More from Scrip